罗格列酮对2型糖尿病患者血清高敏C反应蛋白的影响  

Effects of Rosiglitazone on hypersensitivity C-reactive protein in type 2 diabetic patients

作　　者：周蓓[1] 陶少平[1] 杭宇[1] 

机构地区：[1]皖南医学院附属第二医院内分泌科,安徽芜湖241000

出　　处：《重庆医学》2010年第3期292-293,共2页Chongqing medicine

基　　金：宣城市科学技术局科技计划资助项目(LX-0501)

摘　　要：目的了解罗格列酮类药物对糖尿病患者降糖以外的作用。方法选择2型糖尿病患者68例,其中2型糖尿病并发大血管病变36例(A组),无大血管病变32例(B组),并选择30例健康者作为对照(C组)。分别测定3组患者血清高敏C反应蛋白(hsCRP)水平,并观察罗格列酮治疗前后A组血清hsCRP、血糖等变化。结果A、B组血清hsCRP水平均高于C组,A组明显高于B组;A组罗格列酮治疗后血清hsCRP水平、空腹血糖(FBG)、糖化血红蛋白(HbA1c)水平均明显下降。结论罗格列酮类能明显抑制炎症反应,发挥其对大血管的保护作用。Objective To study the effects of Rosiglitazone on hypersensitivity C-reactive protein（hsCRP）in type 2 diabetic patients.Methods The 68 cases of type 2 diabetic patients were divided into two groups（36 cases with macrovascular complication and 32 cases without macrovascular complication）and 30 healthy subjects served as the control group.The serum hsCRP was determined by immunoturbidimetry.The changes were observed before and after Rosiglitazone treatment.Results The level of hsCRP in diabetic macroangiopathic group was significantly higher than non-macroangiopathic group and the control group.After Rosiglitazone treatment,the levels of hsCRP,FBG,HbA1c reduced remarkably.Conclusion Rosiglitazone can decrease inflammation and improve the prognosis of patients with macroangiopathy.

关 键 词：罗格列酮 C反应蛋白 糖尿病 2型 大血管病变 

分 类 号：R587.1[医药卫生—内分泌] R977.15[医药卫生—内科学]